The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-21 and is reviewed periodically as new material appears.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
== References == Anderson, G.B., (1999). "Epidemiological features of chronic low back pain". The Lancet (1) 354 Langevin, H.M., Bouffard, N.A., Badger, G.J., Churchill, D.L., Howe, A.K., (2006). "Subcutaneous tissue fibroblasts cytoskeletal remodeling induced by acupuncture: evidence for a mechanotransduction-based mechanism". J Cell Physiol (3) 207 Langevin, H.M., Churchill, D.L., Cipolla, M.J., (2001). "Mechanical signalling through connective tissue: A mechanism for the therapeutic effect of acupuncture". FASEB J (1) 15
The addition of mirtazapine to a monoamine oxidase inhibitor, while potentially having typical or idiosyncratic (unique to the individual) reactions not herein described, does not appear to cause serotonin syndrome. This is per the fact that the 5-HT2A receptor is the predominant serotonin receptor thought to be involved in the pathophysiology of serotonin syndrome (with the 5-HT1A receptor seeming to be protective). Mirtazapine is a potent 5-HT2A receptor antagonist, and cyproheptadine, a medication that shares this property, mediates recovery from serotonin syndrome and is an antidote against it. There is a possible interaction that results in a hypertensive crisis when mirtazapine is given to a patient who has already been on steady doses of clonidine. This involves a subtle consideration, when patients have been on chronic therapy with clonidine and suddenly stop the dosing, a rapid hypertensive rebound sometimes (20%) occurs from increased sympathetic outflow. Clonidine's blood pressure lowering effects are due to stimulation of presynaptic α2 autoreceptors in the CNS which suppress sympathetic outflow. Mirtazapine itself blocks these same α2 autoreceptors, so the effect of adding mirtazapine to a patient stabilized on clonidine may precipitate withdrawal symptoms. Mirtazapine has been used as a hallucinogen antidote to block the effects of serotonergic psychedelics like psilocybin and lysergic acid diethylamide (LSD).
== External links == "Motixafortide (Code C88309)". NCI Thesaurus. Archived from the original on 18 January 2017. Clinical trial number NCT03246529 for "A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM (GENESIS)" at ClinicalTrials.gov
Sources: en.wikipedia.org
== Medical significance == Pathogenic (heterozygous) variants in YARS1 have been associated with peripheral nervous system dysfunction called type C dominant intermediate Charcot-Marie-Tooth neuropathy (CMTDIC).
=== Reflection of the target molecule === The first step is the production of the target's enantiomer. In the case of peptides and small proteins that are produced synthetically, an enantiomer is made using synthetic D-amino acids. If the target is a larger protein molecule, beyond synthetic abilities, the enantiomer of an epitope is produced.
Aya Majzoub, Amnesty International's Deputy Regional Director for the Middle East and North Africa, described the attack as a violation of international law that needed to be investigated as a war crime, and that it "seriously endangered the lives of civilians, many of whom were hospitalized and displaced, and whose homes and cars caught fire". Lebanese state media reported that Dhayra and other areas along the western section of the border came under "continuous" bombardment overnight. In the early morning it was reported that multiple people were suffering from symptoms of suffocation after the IDF allegedly fired white phosphorus shells on the village. Three people were injured after an anti-tank missile from Lebanon landed in the Israeli town of Metula. Hezbollah announced that five of its members were killed on the same day but it was unclear if any had involvement in the border infiltration. On 19 October, the Lebanese Armed Forces said that one person was killed and another injured after a group of seven Iranian journalists were targeted with machine guns by Israel, although Iranian state media denied the claim and said that all its journalists were "alive and healthy". UNIFIL peacekeepers said that one person was killed when civilians were caught in a cross-fire at the border. The Lebanese Army requested assistance by UNIFIL to de-escalate the situation, and Israel was asked to suspend fire to allow the rescue operation to proceed.
Sources: en.wikipedia.org
Auditory evoked potentials (AEP) can be used to trace the signal generated by a sound through the ascending auditory pathway. The evoked potential is generated in the cochlea, goes through the cochlear nerve, through the cochlear nucleus, superior olivary complex, lateral lemniscus, to the inferior colliculus in the midbrain, on to the medial geniculate body, and finally to the cortex. Auditory evoked potentials (AEPs) are a subclass of event-related potentials (ERPs). ERPs are brain responses that are time-locked to some "event", such as a sensory stimulus, a mental event (such as recognition of a target stimulus), or the omission of a stimulus. For AEPs, the "event" is a sound. AEPs (and ERPs) are very small electrical voltage potentials originating from the brain recorded from the scalp in response to an auditory stimulus, such as different tones, speech sounds, etc. Brainstem auditory evoked potentials are small AEPs that are recorded in response to an auditory stimulus from electrodes placed on the scalp. AEPs serve for assessment of the functioning of the auditory system and neuroplasticity. They can be used to diagnose learning disabilities in children, aiding in the development of tailored educational programs for those with hearing and or cognition problems.
=== Australia === An Australian edition was briefly published in early 2004, for less than six months. The Australian edition consisted mostly of content from the UK edition, along with news on the local games industry.
==== New Zealand ==== Rosiglitazone was withdrawn from the New Zealand market April 2011 because Medsafe concluded the suspected cardiovascular risks of the medicine for patients with type 2 diabetes outweigh its benefits.
The US Navy has actively participated in the Saudi-led naval blockade of Houthi-controlled territory in Yemen, which humanitarian organizations argue has been the main contributing factor to the outbreak of famine in Yemen. The four-month long Battle of Aden (2015) occurred between 25 March 2015 and 22 July. According to a 2015 September report by Esquire magazine, the Houthis, once the outliers, are now one of the most stable and organised social and political movements in Yemen. The power vacuum created by Yemen's uncertain transitional period has drawn more supporters to the Houthis. Many of the formerly powerful parties, now disorganised with an unclear vision, have fallen out of favour with the public, making the Houthis—under their newly branded Ansar Allah name—all the more attractive. Houthi spokesperson Mohamed Abdel Salam stated that his group had spotted messages between the UAE and Saleh three months before his death. He told Al-Jazeera that there was communication between Saleh, UAE and a number of other countries such as Russia and Jordan through encrypted messages. The alliance between Saleh and the Houthi broke down in late 2017, with armed clashes occurring in Sanaa from 28 November. Saleh declared the split in a televised statement on 2 December, calling on his supporters to take back the country and expressed openness to a dialogue with the Saudi-led coalition. On 4 December 2017, Saleh's house in Sanaa was assaulted by fighters of the Houthi movement, according to residents. Saleh was killed by the Houthis on the same day.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.